Effects of alkalization therapy on chemotherapy in metastatic or recurrent pancreatic cancer, retrospective study

Effects of alkalization therapy on chemotherapy in metastatic or recurrent pancreatic cancer, retrospective study - Alkalization therapy with chemotherapy in advanced pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035659

Enrollment

Registered

2019-01-24

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with metastatic or recurrent pancreatic cancer who were treated at the Karasuma Wada Clinic between April 2015 and December 2017. Patients who received alkalization therapy. Patients who agreed written informed consent.

Exclusion criteria

Exclusion criteria: Patients who could not follow the alkalization therapy and/or visited our clinic less than 3 times.

Design outcomes

Primary

Measure	Time frame
Overall survival (OS) from diagnosis or recurrence OS from the start of alkalization therapy Urine pH before and after alkalization therapy	—

Countries

Japan

Contacts

Public ContactReo Hamaguchi

Japanese Society on Inflammation and Metabolism in Cancer Japanese Society on Inflammation and Metabolism in Cancer, working group

reo-h@nifty.com+81-75-223-3223

Outcome results